NRIX vs. SWTX, RNA, RARE, PTGX, AAPG, SRRK, MLTX, MTSR, VKTX, and KYMR
Should you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.
Nurix Therapeutics vs. Its Competitors
SpringWorks Therapeutics (NASDAQ:SWTX) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.
SpringWorks Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.
SpringWorks Therapeutics has a net margin of -115.60% compared to Nurix Therapeutics' net margin of -369.40%. Nurix Therapeutics' return on equity of -47.49% beat SpringWorks Therapeutics' return on equity.
In the previous week, Nurix Therapeutics had 15 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 19 mentions for Nurix Therapeutics and 4 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 0.93 beat Nurix Therapeutics' score of 0.83 indicating that SpringWorks Therapeutics is being referred to more favorably in the media.
SpringWorks Therapeutics presently has a consensus price target of $52.57, suggesting a potential upside of 11.88%. Nurix Therapeutics has a consensus price target of $30.18, suggesting a potential upside of 144.15%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than SpringWorks Therapeutics.
Nurix Therapeutics has lower revenue, but higher earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Nurix Therapeutics beats SpringWorks Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Nurix Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nurix Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NRIX) was last updated on 7/8/2025 by MarketBeat.com Staff
Free NRIX Stock Alerts